Landscapes / Companies
AvenCell Europe GmbH not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 1
Drugs
2
in active trials · 7 in all
Trials
1 active
5 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1 | May 2027Phase 1 trial completes | |||
| Next date | May 2027 · Phase 1 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | ||||
| Open drug page | |||||
— |
Phase 1 | May 2027Phase 1 trial completes | |||
| Next date | May 2027 · Phase 1 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | ||||
| Open drug page | |||||
About
- No active trial
- GEM333, GEM3PSCA, TM123, UniCAR02-T, UniCAR02-T-pPSMA
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021